Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 83, 2023 - Issue 1
Submit an article Journal homepage
148
Views
0
CrossRef citations to date
0
Altmetric
Articles

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms

Susanne Lilleskarea Department of Medicine, Stavanger University Hospital, Stavanger, NorwayView further author information
,
Marta Vorlandb Department of Cancer Genomics, Haukeland University Hospital, Bergen, NorwayView further author information
,
Anh Khoi Voc Department of Medicine, Haukeland University Hospital, Bergen, NorwayView further author information
,
Aasne K. Aarsandd Norwegian Porphyria Centre and Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway;e Norwegian Organization for Quality Improvement of Laboratory Examinations, Haraldsplass Deaconess Hospital, Bergen, NorwayView further author information
&
Håkon Reikvamc Department of Medicine, Haukeland University Hospital, Bergen, Norway;f Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, NorwayCorrespondence[email protected]
View further author information
Pages 3-7 | Received 17 Mar 2022, Accepted 12 Nov 2022, Published online: 07 Dec 2022

References

  • Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol. 2016;91(1):50–58.
  • Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168–2181.
  • Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390.
  • Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405.
  • Al Assaf C, Van Obbergh F, Billiet J, et al. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica. 2015;100(7):893–897.
  • Rumi E, Pietra D, Pascutto C, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–1069.
  • Ojeda MJ, Bragós IM, Calvo KL, et al. CALR, JAK2 and MPL mutation status in argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms. Hematology. 2018;23(4):208–211.
  • Cordua S, Kjaer L, Skov V, et al. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a danish general population. Blood. 2019;134(5):469–479.
  • Sun C, Zhou X, Zou ZJ, et al. Clinical manifestation of calreticulin gene mutations in essential thrombocythemia without janus kinase 2 and MPL mutations: a chinese cohort clinical study. Chin Med J. 2016;129(15):1778–1783.
  • Rumi E, Pietra D, Ferretti V, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–1551.
  • Tefferi A, Nicolosi M, Mudireddy M, et al. Driver mutations and prognosis in primary myelofibrosis: mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018;93(3):348–355.
  • Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416–1430.
  • Venugopal S, Mascarenhas J. Novel therapeutics in myeloproliferative neoplasms. J Hematol Oncol. 2020;13(1):162.
  • Larsen TS, Christensen JH, Hasselbalch HC, et al. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol. 2007;136(5):745–751.
  • Almedal H, Vorland M, Aarsand AK, et al. Myeloproliferative neoplasms and JAK2 mutations. J Nor Med Ass. 2016;136(22):1889–1894.
  • Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431–438.
  • Pedersen KM, Bak M, Sørensen AL, et al. Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study. Cancer Med. 2018;7(11):5796–5802.
  • Lindholm Sørensen A, Hasselbalch HC. Smoking and philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol. 2016;97(1):63–69.
  • Jayasuriya NA, Kjaergaard AD, Pedersen KM, et al. Smoking, blood cells and myeloproliferative neoplasms: meta-analysis and Mendelian randomization of 2·3 million people. Br J Haematol. 2020;189(2):323–334.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.